Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 191 to 200 of 1514 total matches.
Oat Bran for Lowering Blood Lipids
The Medical Letter on Drugs and Therapeutics • Dec 02, 1988 (Issue 780)
, Vol. 30 (Issue 780) December 2, 1988, pp. 111-112
Copyright The Medical Letter
UNAUTHORIZED ...
Oat bran, the ground inner husk of the grain, has recently become popular as a dietary means of lowering blood lipids. It is available both separately and as a constituent of oatmeal, which is the ground product of the whole grain. Oat bran and oatmeal are available in various breakfast cereals and can also be used in baked goods, such as muffins or bread. Some of these sources are listed in the table on page 112.
Cefixime - A New Oral Cephalosporin
The Medical Letter on Drugs and Therapeutics • Aug 11, 1989 (Issue 798)
The Medical Letter, Vol. 31 (Issue 798) August 11, 1989, pp. 73-75
Copyright The Medical Letter ...
Cefixime (Suprax - Lederle), an oral cephalosporin antibiotic, was recently approved for marketing by the US Food and Drug Administration. Claimed to be the first oral third-generation cephalosporin, the new drug is offered for once-a-day treatment of otitis media, pharyngitis, bronchitis and urinary tract infections.
Fluconazole
The Medical Letter on Drugs and Therapeutics • May 18, 1990 (Issue 818)
of the drug reach 50% to
The Medical Letter, Vol. 32 (Issue 818) May 18, 1990, pp. 50-52
Copyright ...
Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.
Fluoxetine (Prozac) Revisited
The Medical Letter on Drugs and Therapeutics • Sep 07, 1990 (Issue 826)
. The most common adverse
The Medical Letter, Vol. 32 (Issue 826) September 7, 1990, pp. 83-85
Copyright ...
In the short time since fluoxetine (Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports, however, have questioned its safety.
Health Problems in the Persian Gulf
The Medical Letter on Drugs and Therapeutics • Feb 22, 1991 (Issue 838)
to four hours (CD Ericsson et al,
JAMA, 263:257, 1990).
The Medical Letter, Vol. 33 (Issue 838) February ...
With the deployment of hundreds of thousands of troops in Saudi Arabia, health problems endemic to the Arabian Peninsula may be coming to the attention of physicians in the USA and other areas.
Ofloxacin
The Medical Letter on Drugs and Therapeutics • Jul 26, 1991 (Issue 849)
. Cerebrospinal fluid concentrations have not been studied adequately.
The Medical Letter, Vol. 33 (Issue 849 ...
Ofloxacin (Floxin - McNeil, Ortho), a new fluoroquinolone antibacterial agent, was recently marketed in the USA for oral treatment of various infections caused by susceptible microorganisms. Ofloxacin is the third fluoroquinolone to become available in this country. Norfloxacin (Noroxin - Medical Letter, 29:25, 1987) is marketed only for treatment of urinary tract infections. Ciprofloxacin (Cipro - Medical Letter, 30:11, 1988), like ofloxacin, is approved for use in a variety of infections.
Foscarnet
The Medical Letter on Drugs and Therapeutics • Jan 10, 1992 (Issue 861)
, Vol. 34 (Issue 861) January 10, 1992, pp. 3-4
Copyright The Medical Letter
UNAUTHORIZED FORWARDING ...
Phosphonoformic acid or foscarnet (Foscavir - Astra), a synthetic antiviral drug, has now been approved by the US Food and Drug Administration for intravenous (IV) treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis occurs in up to 30% of patients with AIDS and often causes blindness (MD de Smet and RB Nussenbatt, JAMA, 266:3019, Dec 4, 1991).
Nabumetone - A New Nsaid
The Medical Letter on Drugs and Therapeutics • Apr 17, 1992 (Issue 868)
taking the drug (A Morice et al, Postgrad Med J, 67:1021, 1991).
The Medical Letter, Vol. 34 (Issue 868 ...
Nabumetone (Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers.
New Recommendation for Immunization Against Pertussis and Hepatitis B
The Medical Letter on Drugs and Therapeutics • Jul 24, 1992 (Issue 875)
The Medical Letter, Vol. 34 (Issue 875) July 24, 1992, pp. 69-71
Copyright The Medical Letter
UNAUTHORIZED ...
The Immunization Practices Advisory Committee of the US Public Health Service now recommends immunizing all infants and some adolescents against hepatitis B and using a new diphtheria-tetanus-acellular pertussis vaccine (DTaP; ACEL-IMUNE - Lederle) for the fourth and fifth doses of DTP, usually given at 15 to 18 months of age and before school entry (Morbid Mortal Weekly Rep, 40 RR-13:1, November 22, 1991; Morbid Mortal Weekly Rep, 41 RR-1:1, Feb 7, 1992). The Committee on Infectious Diseases of the American Academy of Pediatrics has made similar recommendations but would extend...
Enoxacin - A New Fluoroquinolone
The Medical Letter on Drugs and Therapeutics • Nov 13, 1992 (Issue 883)
with diminished renal function (A Fitton, Clin Pharmacokinet, 22 suppl 1:1, 1992).
The Medical Letter, Vol. 34 ...
Enoxacin (en ox' a sin; Penetrex - Rh ne-Poulenc Rorer), a fluoroquinolone antimicrobial for oral use, has now been marketed in the USA for treatment of urinary tract infections and uncomplicated urethral or cervical gonorrhea.